至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Rational development of a combined mRNA vaccine against COVID-19 and influenza

npj Vaccines. 2022-07; 
Qing Ye , Mei Wu , Chao Zhou , Xishan Lu , Baoying Huang , Ning Zhang , Hui Zhao , Hang Chi , Xiaojing Zhang , Dandan Ling , Rong-Rong Zhang , Zhuofan Li , Dan Luo , Yi-Jiao Huang , Hong-Ying Qiu , Haifeng Song , Wenjie Tan , Ke Xu , Bo Ying , Cheng-Feng Qin
Products/Services Used Details Operation
Peptide Library Services Published in partnership with the Sealy Institute for Vaccine Sciences using the influenza A virus (A/California/07/2009) HA peptide pool and SARS-CoV-2 RBD peptide pool (peptides are 15mers, with 11 amino acid overlaps, Genscript) at 1.5 µg/ml per peptide. Get A Quote

摘要

As the world continues to experience the COVID-19 pandemic, seasonal influenza remain a cause of severe morbidity and mortality globally. Worse yet, coinfection with SARS-CoV-2 and influenza A virus (IAV) leads to more severe clinical outcomes. The development of a combined vaccine against both COVID-19 and influenza is thus of high priority. Based on our established lipid nanoparticle (LNP)-encapsulated mRNA vaccine platform, we developed and characterized a novel mRNA vaccine encoding the HA antigen of influenza A (H1N1) virus, termed ARIAV. Then, ARIAV was combined with our COVID-19 mRNA vaccine ARCoV, which encodes the receptor-binding domain (RBD) of the SARS-CoV-2 S protein, to formulate the final combine... More

关键词